REVVITY, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 111.9 USD | -1.24% |
|
-1.21% | +2.33% |
| May. 14 | Transcript : Revvity, Inc. Presents at Bank of America Health Care Conference 2024, May-14-2024 08:40 AM | |
| Apr. 30 | TD Cowen Adjusts Price Target on Revvity to $130 From $123 | MT |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
- The company's Refinitiv ESG score, based on a ranking of the company relative to its industry, comes out particularly well.
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- The potential for earnings per share (EPS) growth in the coming years appears limited according to current analyst estimates.
- One of the major weak points of the company is its financial situation.
- With an expected P/E ratio at 56.86 and 42.23 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- Based on current prices, the company has particularly high valuation levels.
- The company is not the most generous with respect to shareholders' compensation.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Advanced Medical Equipment & Technology
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| +2.33% | 13.98B | B+ | ||
| +7.87% | 223B | B | ||
| +11.83% | 195B | B- | ||
| +18.87% | 144B | B- | ||
| +30.03% | 111B | A- | ||
| +2.32% | 65.19B | A- | ||
| +14.15% | 53.02B | B+ | ||
| +2.68% | 50.28B | B+ | ||
| +6.60% | 44.15B | A | ||
| +1.85% | 36.45B | - |
Investor Rating
Trading Rating
ESG Refinitiv
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
Environment
Emissions
Innovation
Use of resources
Governance
CSR Strategy
Management
Shareholders
Controversy
Controversy
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- RVTY Stock
- Ratings Revvity, Inc.
